Protagonist Therapeutics, Inc. PTGX
124.67 USD -0.16 (-0.13%)
Regular-session close
124.67 0.00 0.00%
After hours · Nov 17, 4:33 PM ET
121.75 Day range 125.90
77.00 52-week range 160.81
- YTD
- +42.74%
- 1 year
- +47.07%
News
zacks.com How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6% The average of price targets set by Wall Street analysts indicates a potential upside of 37.6% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is…benzinga.com HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221 HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.
zacks.com Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates Protagonist Therapeutics (PTGX) came out with quarterly earnings of $3.07 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to a loss of $0.62 per share a year ago.
zacks.com Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
seekingalpha.com Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs, robust liquidity, and a $300 million buyback. PTGX secured lucrative back-end royalties and milestones…benzinga.com TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160 TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.
defenseworld.net Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT) Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
defenseworld.net Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX) Genelux (NASDAQ: GNLX - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
zacks.com Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near…
defenseworld.net Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
defenseworld.net Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stock Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 63,548 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an…
defenseworld.net Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $7,902,361.38 in Stock Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,174 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The shares were…
defenseworld.net Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX Hsbc Holdings PLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 1,260.9% during the second quarter, according to its most recent filing with the Securities and Exchange…
seekingalpha.com Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
accessnewswire.com Protagonist Therapeutics Announces $300 Million Share Repurchase Program NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the…
accessnewswire.com Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
seekingalpha.com Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
marketbeat.com Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia…
fool.com Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. J&J's portfolio primarily includes small biotech and medtech companies. Its largest investment is in the company in its portfolio with the largest market cap.
accessnewswire.com Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit…
